Contrast enhanced mammography in breast cancer surveillance
Authors:
Open Access
- 25 March 2023
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 199 (2) , 221-230
Abstract
Purpose: Mammography (MG) is the standard imaging in surveillance of women with a personal history of breast cancer or DCIS (PHBC), supplemented with ultrasound. Contrast Enhanced Mammography (CEM) has higher sensitivity than MG and US. We report the performance of CEM compared with MG ± US. Methods: A retrospective study of patients undergoing their first surveillance CEM in an Australian hospital setting between June 2006 and October 2020. Cases where a patient was recalled for assessment were identified, recording radiology, pathology and treatment details. Blinded re-reading of recalled cases was performed to determine the contribution of contrast. Use of surveillance US across the board was assessed for the period. Results: 73/1191 (6.1%) patients were recalled. 35 (48%) were true positives (TP), with 26 invasive cancers and 9 cases of DCIS, while 38 (52%) were false positive (FP) with a positive predictive value (PPV) 47.9%. 32/73 were recalled due to MG findings, while 41/73 were only recalled due to Contrast. 14/73 had ‘minimal signs’ with a lesion identifiable on MG with knowledge of the contrast finding, while 27/73 were visible only with contrast. 41% (17/41) recalled due to contrast were TP. Contrast-only TPs were found with low and high mammographic density (MD). Screening breast US reduced by 55% in the year after CEM was implemented. Conclusion: Compared to MG, CEM as a single surveillance modality for those with PHBC has higher sensitivity and comparable specificity, identifying additional malignant lesions that are clinically significant. Investigation of interval cancer and subsequent round outcomes is warranted.Keywords
All Related Versions
This publication has 35 references indexed in Scilit:
- Sensitivity and specificity of mammography and adjunctive ultrasonography to screen for breast cancer in the Japan Strategic Anti-cancer Randomized Trial (J-START): a randomised controlled trialThe Lancet, 2016
- Integration of 3D digital mammography with tomosynthesis for population breast-cancer screening (STORM): a prospective comparison studyThe Lancet Oncology, 2013
- Detection of Breast Cancer With Addition of Annual Screening Ultrasound or a Single Screening MRI to Mammography in Women With Elevated Breast Cancer RiskJAMA, 2012
- MRI for breast cancer screening, diagnosis, and treatmentThe Lancet, 2011
- Accuracy and Outcomes of Screening Mammography in Women With a Personal History of Early-Stage Breast CancerJAMA, 2011
- Diagnosis of second breast cancer events after initial diagnosis of early stage breast cancerBreast Cancer Research and Treatment, 2010
- Mammographic density and the risk of breast cancer recurrence after breast‐conserving surgeryCancer, 2009
- Combined Screening With Ultrasound and Mammography vs Mammography Alone in Women at Elevated Risk of Breast CancerJAMA, 2008
- Impact on survival of early detection of isolated breast recurrences after the primary treatment for breast cancer: a meta-analysisBreast Cancer Research and Treatment, 2008
- MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational studyThe Lancet, 2007